Given the favourable, tumour-selective targeting observed in vitro, we performed ex vivo studies in organoids derived from the clinically relevant KPC (Pdx1-CreERTLSL-KrasG12D/+; LSL-Trp53R172H; Rosa26LSL-tdRFP) genetically engineered mouse model (GEMM) of PDAC. Here, PDX1 is linked to neoplasm.